Clinical

Bristol-Myers Squibb announced that the FDA has placed a clinical hold on 3 combination trials evaluating its programmed death-1 inhibitor nivolumab (Opdivo) in patients with relapsed/refractory multiple myeloma.

A single blood draw that combines the detection of DNA and protein markers could be more sensitive to the earlier detection of pancreatic cancer, according to a new study published in Proceedings of the National Academy of Sciences.

Cellectis, a clinical-stage biotechnology company, was asked by the FDA to place a clinical hold on 2 phase 1 trials evaluating its allogeneic chimeric antigen receptor-T (CAR-T) cell treatments following the report of a fatality in the first patient treated in one of the studies.

Psoriasis severity has been linked to increased risk of death in a new study published in the Journal of Investigative Dermatology. Researchers found that the risk of death increased for patients who had more surface area covered by psoriasis.

Despite trials showing that antitumor necrosis factor (TNF) therapy is safe and effective to treat inflammatory diseases such as inflammatory bowel disease and rheumatoid arthritis, but adherence rates remain low.

The treatment, which was approved nearly 2 decades ago but withdrawn due to safety and efficacy concerns, now has a new indication.

A look at some of the major developments in the chimeric antigen receptor T (CAR-T) cell space.

Results of a combination trial evaluating epacadostat with pembrolizumab in advanced melanoma, to be presented at the upcoming European Society for Medical Oncology (ESMO) 2017 Congress, has found that the treatment is well tolerated and has promising clinical activity.

A once-daily treatment that lasts up to 16 hours post-dose for patients older than 13 years who have attention-deficit/hyperactivity disorder (ADHD) is now available in the United States.

A gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare skin disease that causes the skin to be very fragile and blister easily, has been granted Breakthrough Therapy designation status by the FDA.

The FDA has approved the first chimeric antigen receptor-T (CAR-T) treatment, tisagenlecleucel (Kymriah), for the treatment of B-cell precursor acute lymphoblastic leukemia in certain pediatric and young adult patients. The therapy represents a new frontier in cancer care.

The results of the COMPASS trial testing rivaroxaban plus aspirin in patients with coronary artery disease or peripheral artery disease showed such significant benefits for reducing ischemic events that it was stopped early, explained Deepak Bhatt, MD, MPH, of Brigham and Women's Hospital and Harvard Medical School.

A study published in JCO Precision Oncology has identified an association between genetic inheritance and patients’ response to efficacy and toxicity in the phase 3 ECOG-ACRIN-5103 trial.

For each level of cardiovascular risk, lifestyle factors remain a significant contributor that can be modified to reduce risk. However, some risk will remain nonmodifiable and require therapy, according to panelists during a session on cardiovascular prevention at the European Society of Cardiology Congress 2017, held August 26-30 in Barcelona, Spain.

Trial results that will be presented at the European Society of Cardiology Congress 2017 in Barcelona, Spain, will open up a new window into treatment for patients at risk of major cardiovascular events, explained Steven E. Nissen, MD, of Cleveland Clinic, at the start of the conference.

Chimeric antigen receptor (CAR)-T cells can re-expand in a lymphoma patient months after the initial infusion and can also be active against the patient’s cancer, according to a new study.

Medicinal cannabis has become increasingly accepted in the United States and is commonly used for pain management. Despite its growing popularity as a treatment, there is little evidence available about the harms and benefits of cannabis utilization.

The brains of women are significantly more active than the brains of men, according to the largest functional brain imaging study to date conducted by Amen Clinics. This explains why there are higher rates of some conditions, such as attention-deficit/hyperactivity disorder (ADHD), in men compared with women, who have higher rates of depression.

A new study in the Journal of Clinical Oncology identifies an increased role for physicians in boosting human papillomavirus (HPV) vaccination rates among childhood cancer survivors to reduce their risk of a second cancer.

According to a new study published in Cancer, an annual screening mammogram starting at age 40 has the greatest impact on reducing mortality.

Probiotics are often believed to stimulate healthy immune function, but a new study did not find significant evidence that a supplement of lactobacillus prevents eczema, which is a common precursor to asthma.

Researchers can determine the best treatments for skin disorders, like atopic dermatitis and ringworm, by first observing how they benefit pets with the same conditions.

Study assessed the patterns of care for biologic-dosing outliers and nonoutliers in patients with rheumatoid arthritis.

A new oral dosage form of olaparib (Lynparza) has been approved as maintenance treatment in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.

Researchers from the United States, Netherlands, and Denmark have collaborated on developing a new liquid biopsy test that can detect circulating cell-free DNA in patients with early-stage cancer.

The Institute for Clinical and Economic Review (ICER) released a Final Evidence Report that found an absence of sufficient evidence to confirm the efficacy of abuse-deterrent formulations (ADFs) of opioids in decreasing the opioid abuse levels of the greater population.

A new study, published in the journal Nature, has confirmed the efficacy of a melanoma vaccine targeted against 20 predicted personal tumor neoantigens in 6 patients.

Gastroenterologists favorably view Janus kinase (JAK) inhibitors for utilization in treating inflammatory bowel disease (IBD), according to a recent survey conducted by Decision Resources Group.